Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 5

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients

Authors Anand A Dalal, Meaghan St Charles, Hans V Petersen, et al

Published 9 June 2010 Volume 2010:5 Pages 179—187

DOI https://doi.org/10.2147/COPD.S10988

Review by Single-blind

Peer reviewer comments 2

Anand A Dalal1, Meaghan St Charles2, Hans V Petersen2, Melissa H Roberts2, Christopher M Blanchette2, Kathy Manavi-Zieverink3

1US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC, 2Division of Clinical and Outcomes Research, Lovelace Respiratory Research Institute, Kannapolis USA; 3INC Research, Raleigh; NC, USA

Objective: To estimate the cost-effectiveness of fluticasone propionate–salmeterol combination (FSC) compared to salmeterol for maintenance therapy in severe chronic obstructive pulmonary disease (COPD).

Study design: Pooled economic analysis.

Methods: We performed an economic analysis of pooled data from two randomized clinical trials (combined N = 1554) that evaluated the effect of maintenance therapy with FSC (250/50 μg twice daily) or salmeterol (50 μg twice daily) on exacerbation rates in patients with severe COPD. We calculated exacerbation rates and applied standardized costs to exacerbation-related health care utilization reported in the trials (office, urgent care, and emergency department visits; hospitalizations; and oral corticosteroids and antibiotics) to determine cost differences between FSC and salmeterol treatment outcomes.
Results: Annual rates of any exacerbation and moderate/severe exacerbation were lower in the FSC group than the salmeterol group (4.91 vs 5.78 and 1.32 vs 2.00 respectively, both P < 0.05). Total adjusted annual COPD related exacerbation and therapeutic costs were $4,842 (95% CI; $4,731–$4,952) in the FSC group and $5,066 (95% CI; $4,937–$5,195) in the salmeterol group.

Conclusions: FSC combination therapy is associated with reduced risk of any exacerbation and moderate/severe exacerbation, and incurs lower annual COPD-related health care costs compared to treatment with salmeterol. This analysis demonstrates that FSC therapy may be advantageous from both a clinical and cost-benefit standpoint for patients with severe COPD.
Keywords: COPD, cost-effectiveness analysis, economic, maintenance therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Economic burden of chronic bronchitis in the United States: a retrospective case-control study

Christopher M Blanchette, Melissa H Roberts, Hans Petersen, et al 

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:73-81

Published Date: 13 January 2011

Readers of this article also read:

Tungsten oxide-Au nanosized film composites for glucose oxidation and sensing in neutral medium

Gougis M, Ma D, Mohamedi M

International Journal of Nanomedicine 2015, 10:2939-2950

Published Date: 15 April 2015

Electrospun gelatin/polycaprolactone nanofibrous membranes combined with a coculture of bone marrow stromal cells and chondrocytes for cartilage engineering

He X, Feng B, Huang C, Wang H, Ge Y, Hu R, Yin M, Xu Z, Wang W, Fu W, Zheng J

International Journal of Nanomedicine 2015, 10:2089-2099

Published Date: 17 March 2015

Determination of factors controlling the particle size and entrapment efficiency of noscapine in PEG/PLA nanoparticles using artificial neural networks

Shalaby KS, Soliman ME, Casettari L, Bonacucina G, Cespi M, Palmieri GF, Sammour OA, El Shamy AA

International Journal of Nanomedicine 2014, 9:4953-4964

Published Date: 23 October 2014

Development of a biocompatible nanodelivery system for tuberculosis drugs based on isoniazid-Mg/Al layered double hydroxide

Saifullah B, Arulselvan P, El Zowalaty ME, Fakurazi S, Webster TJ, Geilich BM, Hussein MZ

International Journal of Nanomedicine 2014, 9:4749-4762

Published Date: 9 October 2014

Central airways remodeling in COPD patients

Pini L, Pinelli V, Modina D, Bezzi M, Tiberio L, Tantucci C

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:927-933

Published Date: 1 September 2014

Toxicology of antimicrobial nanoparticlesfor prosthetic devices

Nuñez-Anita RE, Acosta-Torres LS, Vilar-Pineda J, Martínez-Espinosa JC, de la Fuente-Hernández J, Castaño VM

International Journal of Nanomedicine 2014, 9:3999-4006

Published Date: 20 August 2014

Development and characterization of magnetic iron oxide nanoparticles with a cisplatin-bearing polymer coating for targeted drug delivery

Unterweger H, Tietze R, Janko C, Zaloga J, Lyer S, Dürr S, Taccardi N, Goudouri OM, Hoppe A, Eberbeck D, Schubert DW, Boccaccini AR, Alexiou C

International Journal of Nanomedicine 2014, 9:3659-3676

Published Date: 5 August 2014

Relationships between respiratory and airway resistances and activity-related dyspnea in patients with chronic obstructive pulmonary disease

Mahut B, Caumont-Prim A, Plantier L, Gillet-Juvin K, Callens E, Sanchez O, Chevalier-Bidaud B, Bokov P, Delclaux C

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:165-171

Published Date: 6 March 2012